SG/CALL/VERTEX PHARMACEUTICALS/250/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 20:39:23 13/06/2024 BST | ||
| 21.23 EUR | +1.87% |
|
| Current month | +11.74% | ||
| 1 month | +26.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 13/06/24 | 21.23 | +1.87% |
| 12/06/24 | 20.84 | -3.47% |
| 11/06/24 | 21.59 | -0.83% |
| 10/06/24 | 21.77 | +0.28% |
| 07/06/24 | 21.71 | +0.79% |
Delayed Quote Deutsche Boerse AG
Last update June 13, 2024 at 08:39 pm
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SQ6M3R |
| ISIN | DE000SQ6M3R0 |
| Date issued | 21/12/2022 |
| Strike | 250 $ |
| Maturity | 21/06/2024 (6 Days) |
| Parity | 10 : 1 |
| Emission price | 8.09 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.85 € |
|---|---|
| Lowest since issue | 6.8 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 1.916 |
| Difference Strike | -230.7 $ |
| Difference Strike % | -92.29% |
| Intrinsic value | 21.33 |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Warrants
- Warrant